

Sherene Loi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/544541/publications.pdf>

Version: 2024-02-01

258
papers

46,628
citations

3721

89
h-index

1974

206
g-index

263
all docs

263
docs citations

263
times ranked

39832
citing authors

#	ARTICLE	IF	CITATIONS
1	Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2108-2121.	13.9	3,097
2	The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. <i>Annals of Oncology</i> , 2015, 26, 259-271.	0.6	2,122
3	Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis. <i>Journal of the National Cancer Institute</i> , 2006, 98, 262-272.	3.0	1,824
4	Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 425-439.	5.1	1,344
5	Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98. <i>Journal of Clinical Oncology</i> , 2013, 31, 860-867.	0.8	1,342
6	Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 209-219.	13.9	1,239
7	Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1183-1192.	3.0	1,128
8	Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. <i>Annals of Oncology</i> , 2014, 25, 1544-1550.	0.6	1,022
9	Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. <i>Lancet</i> , The, 2020, 396, 1817-1828.	6.3	992
10	Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers. <i>Journal of Clinical Oncology</i> , 2015, 33, 983-991.	0.8	863
11	Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series. <i>Clinical Cancer Research</i> , 2007, 13, 3207-3214.	3.2	839
12	Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 44-59.	5.1	826
13	CD4+ follicular helper T cell infiltration predicts breast cancer survival. <i>Journal of Clinical Investigation</i> , 2013, 123, 2873-2892.	3.9	813
14	Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 1926-1936.	13.9	805
15	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 597-609.	13.9	789
16	Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. <i>Lancet Oncology</i> , The, 2017, 18, 1009-1021.	5.1	716
17	Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor-Positive Breast Carcinomas Through Genomic Grade. <i>Journal of Clinical Oncology</i> , 2007, 25, 1239-1246.	0.8	711
18	Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. <i>Nature Medicine</i> , 2018, 24, 986-993.	15.2	689

#	ARTICLE	IF	CITATIONS
19	Consensus guidelines for the detection of immunogenic cell death. <i>Oncolmmunology</i> , 2014, 3, e955691.	2.1	686
20	Clinical relevance of host immunity in breast cancer: from TILs to the clinic. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 228-241.	12.5	679
21	Neoantigen-directed immune escape in lung cancer evolution. <i>Nature</i> , 2019, 567, 479-485.	13.7	639
22	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
23	Plasma <i>ESR1</i> Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2961-2968.	0.8	573
24	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. <i>Nature</i> , 2018, 554, 189-194.	13.7	572
25	Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. <i>Annals of Oncology</i> , 2019, 30, 397-404.	0.6	538
26	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017, 24, 311-335.	2.4	530
27	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. <i>Journal of Clinical Oncology</i> , 2019, 37, 559-569.	0.8	505
28	Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab. <i>JAMA Oncology</i> , 2015, 1, 448.	3.4	482
29	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	2.4	469
30	Clinical Application of the 70-Gene Profile: The MINDACT Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 729-735.	0.8	449
31	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , 2020, 21, 519-530.	5.1	441
32	RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2016, 22, 1499-1509.	3.2	428
33	Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. <i>Annals of Oncology</i> , 2019, 30, 405-411.	0.6	419
34	Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 7142-7147.	3.3	413
35	Silencing of <i>Irf7</i> pathways in breast cancer cells promotes bone metastasis through immune escape. <i>Nature Medicine</i> , 2012, 18, 1224-1231.	15.2	406
36	CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 11091-11096.	3.3	406

#	ARTICLE	IF	CITATIONS
37	The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. <i>Cancer Discovery</i> , 2018, 8, 1390-1403.	7.7	397
38	Dissecting the Heterogeneity of Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 1879-1887.	0.8	388
39	Intratumoral heterogeneity in cancer progression and response to immunotherapy. <i>Nature Medicine</i> , 2021, 27, 212-224.	15.2	376
40	Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 487-504.	3.2	355
41	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1bâ€² trial. <i>Lancet Oncology</i> , The, 2019, 20, 371-382.	5.1	327
42	<i>PIK3CA</i> mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptorâ€²-positive breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 10208-10213.	3.3	324
43	Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. <i>Cancer Treatment Reviews</i> , 2013, 39, 935-946.	3.4	308
44	Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling. <i>Clinical Cancer Research</i> , 2012, 18, 1341-1351.	3.2	303
45	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. <i>Seminars in Cancer Biology</i> , 2018, 52, 16-25.	4.3	303
46	Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors. <i>Cancer Research</i> , 2011, 71, 4809-4820.	0.4	302
47	Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. <i>BMC Genomics</i> , 2008, 9, 239.	1.2	300
48	Obesity and Outcomes in Premenopausal and Postmenopausal Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1686-1691.	1.1	290
49	A Three-Gene Model to Robustly Identify Breast Cancer Molecular Subtypes. <i>Journal of the National Cancer Institute</i> , 2012, 104, 311-325.	3.0	272
50	Precision medicine for metastatic breast cancerâ€² limitations and solutions. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 693-704.	12.5	272
51	Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptorâ€²-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1169-1178.	0.8	266
52	Adenosine Receptor 2A Blockade Increases the Efficacy of Antiâ€²PD-1 through Enhanced Antitumor T-cell Responses. <i>Cancer Immunology Research</i> , 2015, 3, 506-517.	1.6	262
53	Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. <i>Journal of Clinical Investigation</i> , 2017, 127, 929-941.	3.9	251
54	Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptorâ€²-Positive/Human Epidermal Growth Factor Receptor 2â€²-Negative Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2804-2811.	3.2	249

#	ARTICLE	IF	CITATIONS
55	<i>PIK3CA</i> Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3212-3220.	0.8	231
56	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. <i>Modern Pathology</i> , 2016, 29, 1155-1164.	2.9	230
57	Combined immune checkpoint blockade as a therapeutic strategy for <i>BRCA1</i> -mutated breast cancer. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	227
58	Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. <i>Lancet Oncology</i> , The, 2017, 18, 52-62.	5.1	225
59	Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 540-551.	4.3	222
60	Pervasive chromosomal instability and karyotype order in tumour evolution. <i>Nature</i> , 2020, 587, 126-132.	13.7	221
61	Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. <i>Lancet Oncology</i> , The, 2020, 21, 1283-1295.	5.1	213
62	<i>PIK3CA</i> Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1334-1339.	0.8	201
63	Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 1996-2004.	0.8	194
64	The genomic landscape of breast cancer and its interaction with host immunity. <i>Breast</i> , 2016, 29, 241-250.	0.9	194
65	Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). <i>Oncologist</i> , 2016, 21, 1165-1175.	1.9	183
66	Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. <i>Nature Medicine</i> , 2020, 26, 1054-1062.	15.2	181
67	Relevance of tumor-infiltrating lymphocytes in breast cancer. <i>BMC Medicine</i> , 2015, 13, 202.	2.3	177
68	Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 28-33.	3.2	173
69	Atezolizumab and <i>nab</i> -Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1005-1016.	3.0	171
70	Combined CDK4/6 and PI3K± Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2017, 77, 6340-6352.	0.4	163
71	Tissue-resident memory T cells in breast cancer control and immunotherapy responses. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 341-348.	12.5	159
72	Triple-negative breast cancer: recent treatment advances. <i>F1000Research</i> , 2019, 8, 1342.	0.8	152

#	ARTICLE	IF	CITATIONS
73	RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. <i>Breast Cancer Research</i> , 2015, 17, 24.	2.2	149
74	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immunology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	2.1	142
75	Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2013, 105, 960-967.	3.0	138
76	KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1000-1000.	0.8	135
77	Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis. <i>Cancer Research</i> , 2016, 76, 4372-4382.	0.4	130
78	Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. <i>JCI Insight</i> , 2018, 3, .	2.3	128
79	Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses. <i>Frontiers in Immunology</i> , 2018, 9, 70.	2.2	120
80	The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE". <i>PLoS Medicine</i> , 2016, 13, e1002204.	3.9	119
81	RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy. <i>JAMA Oncology</i> , 2017, 3, 227.	3.4	118
82	Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. <i>Pathology</i> , 2017, 49, 141-155.	0.3	112
83	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021, 7, 150.	2.3	112
84	Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 305-315.	0.8	109
85	Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. <i>Oncologist</i> , 2017, 22, 1028-1038.	1.9	108
86	Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC). <i>Breast</i> , 2017, 34, S27-S30.	0.9	107
87	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	2.3	106
88	Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. <i>Journal of Clinical Oncology</i> , 2017, 35, 1008-1008.	0.8	99
89	Research Resource: Nuclear Receptors as Transcriptome: Discriminant and Prognostic Value in Breast Cancer. <i>Molecular Endocrinology</i> , 2013, 27, 350-365.	3.7	98
90	Incidence of Malignancies in Heart and/or Lung Transplant Recipients: A Single-Institution Experience. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 845-849.	0.3	97

#	ARTICLE	IF	CITATIONS
91	Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. <i>Oncolimmunology</i> , 2013, 2, e24720.	2.1	96
92	Tumor <i>PIK3CA</i> Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data. <i>Journal of Clinical Oncology</i> , 2018, 36, 981-990.	0.8	95
93	<i>PIK3CA</i> mutations in breast cancer: reconciling findings from preclinical and clinical data. <i>Breast Cancer Research</i> , 2014, 16, 201.	2.2	94
94	Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. <i>Breast Cancer Research</i> , 2016, 18, 43.	2.2	90
95	CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy. <i>Cancer Research</i> , 2017, 77, 5652-5663.	0.4	90
96	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2020, 6, 16.	2.3	90
97	An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers. <i>Breast Cancer Research</i> , 2016, 18, 121.	2.2	89
98	Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. <i>Nature Communications</i> , 2017, 8, 606.	5.8	89
99	Prediction of breast cancer prognosis using gene set statistics provides signature stability and biological context. <i>BMC Bioinformatics</i> , 2010, 11, 277.	1.2	87
100	Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions. <i>Frontiers in Oncology</i> , 2017, 7, 156.	1.3	87
101	Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis. <i>Breast Cancer Research</i> , 2019, 21, 94.	2.2	87
102	Identification of Functional Networks of Estrogen- and c-Myc-Responsive Genes and Their Relationship to Response to Tamoxifen Therapy in Breast Cancer. <i>PLoS ONE</i> , 2008, 3, e2987.	1.1	85
103	Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). <i>European Journal of Cancer</i> , 2017, 85, 133-145.	1.3	84
104	Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i> -Mutant Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 198-213.	7.7	83
105	PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus <i>nab</i> -Paclitaxel-Treated Advanced Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1733-1743.	3.0	83
106	Checkpoint blockade in the treatment of breast cancer: current status and future directions. <i>British Journal of Cancer</i> , 2018, 119, 4-11.	2.9	82
107	<i>PIK3CA</i> Genotype and a <i>PIK3CA</i> Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e53292.	1.1	80
108	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811.	7.7	79

#	ARTICLE	IF	CITATIONS
109	Identification of Novel Ras-Cooperating Oncogenes in <i>Drosophila melanogaster</i> : A RhoGEF/Rho-Family/JNK Pathway Is a Central Driver of Tumorigenesis. <i>Genetics</i> , 2011, 188, 105-125.	1.2	77
110	Immune Infiltration in Invasive Lobular Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 768-776.	3.0	76
111	The T cell differentiation landscape is shaped by tumour mutations in lung cancer. <i>Nature Cancer</i> , 2020, 1, 546-561.	5.7	74
112	Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab. <i>JAMA Oncology</i> , 2016, 2, 1040.	3.4	73
113	Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTO Phase III Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3581-3588.	3.2	73
114	Uncovering the genomic heterogeneity of multifocal breast cancer. <i>Journal of Pathology</i> , 2015, 236, 457-466.	2.1	72
115	Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma—The RAPPOR Trial. <i>European Urology</i> , 2022, 81, 364-372.	0.9	70
116	Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4 ⁺ Foxp3 ⁺ Cell-Mediated Modulation of CD103 ⁺ Dendritic Cells. <i>Cancer Immunology Research</i> , 2018, 6, 1069-1081.	1.6	67
117	A community-based model of rapid autopsy in end-stage cancer patients. <i>Nature Biotechnology</i> , 2016, 34, 1010-1014.	9.4	66
118	Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2 ⁻ ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. <i>Clinical Cancer Research</i> , 2022, 28, 3433-3442.	3.2	65
119	A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. <i>Lancet Oncology</i> , The, 2012, 13, e240-e248.	5.1	64
120	Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC. <i>Cancer Immunology Research</i> , 2017, 5, 871-884.	1.6	63
121	A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells. <i>Cancer Research</i> , 2017, 77, 1296-1309.	0.4	61
122	Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER ⁺ Advanced Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 309-317.	3.0	60
123	Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 527-537.	3.3	59
124	Biology of breast cancer during pregnancy using genomic profiling. <i>Endocrine-Related Cancer</i> , 2014, 21, 545-554.	1.6	58
125	Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2-Advanced Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 419-430.	3.0	55
126	Phase 2 study of pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1088-1088.	0.8	55

#	ARTICLE	IF	CITATIONS
127	Beyond trastuzumab: New treatment options for HER2-positive breast cancer. <i>Breast</i> , 2011, 20, S20-S27.	0.9	53
128	Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). <i>Science Signaling</i> , 2018, 11, .	1.6	53
129	Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. <i>European Journal of Cancer</i> , 2018, 104, 21-31.	1.3	53
130	Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. <i>Clinical Chemistry</i> , 2019, 65, 1405-1413.	1.5	53
131	Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer. <i>BMC Medical Genomics</i> , 2009, 2, 37.	0.7	51
132	Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. <i>Modern Pathology</i> , 2017, 30, 952-963.	2.9	50
133	Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. <i>Oncotarget</i> , 2016, 7, 67686-67698.	0.8	50
134	Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial. <i>Breast</i> , 2020, 49, 55-62.	0.9	49
135	Characterization and Clinical Evaluation of CD10+ Stroma Cells in the Breast Cancer Microenvironment. <i>Clinical Cancer Research</i> , 2012, 18, 1004-1014.	3.2	46
136	Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC). <i>Breast</i> , 2019, 48, S44-S48.	0.9	46
137	Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. <i>Nature Communications</i> , 2020, 11, 6335.	5.8	46
138	Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer. <i>BMC Medicine</i> , 2015, 13, 177.	2.3	45
139	The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling. <i>Cancer Research</i> , 2016, 76, 4236-4248.	0.4	45
140	Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. <i>Annals of Oncology</i> , 2016, 27, 1860-1866.	0.6	45
141	Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 2361-2374.	0.8	45
142	Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition. <i>Current Opinion in Oncology</i> , 2012, 24, 623-634.	1.1	44
143	Persistent Impairment in Cardiopulmonary Fitness after Breast Cancer Chemotherapy. <i>Medicine and Science in Sports and Exercise</i> , 2019, 51, 1573-1581.	0.2	42
144	Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. <i>Clinical Cancer Research</i> , 2020, 26, 354-363.	3.2	40

#	ARTICLE	IF	CITATIONS
145	The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 61, 187-194.	2.0	39
146	Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1954-1960.	0.8	39
147	Host Antitumor Immunity Plays a Role in the Survival of Patients With Newly Diagnosed Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 2935-2937.	0.8	39
148	Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5668-5681.	3.2	37
149	Activation of Canonical BMP4-SMAD7 Signaling Suppresses Breast Cancer Metastasis. <i>Cancer Research</i> , 2020, 80, 1304-1315.	0.4	37
150	Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1335.	3.4	36
151	Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer. <i>Cancer Cell</i> , 2020, 37, 623-624.	7.7	35
152	Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC). <i>Cancer Research</i> , 2020, 80, PD5-03-PD5-03.	0.4	34
153	CD73: A potential biomarker for anti-PD-1 therapy. <i>Oncolmmunology</i> , 2015, 4, e1046675.	2.1	33
154	Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5â€‰%Years of Follow-Up. <i>Oncologist</i> , 2021, 26, e749-e755.	1.9	33
155	The tumor microenvironment (TME) and atezolizumab + nab-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1006-1006.	0.8	33
156	Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 3.	2.3	33
157	Clinical implications of prospective genomic profiling of metastatic breast cancer patients. <i>Breast Cancer Research</i> , 2020, 22, 91.	2.2	32
158	The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 271-278.	1.1	31
159	Mouse Models of Tumor Immunotherapy. <i>Advances in Immunology</i> , 2016, 130, 1-24.	1.1	30
160	Tumour infiltrating lymphocytes in breast cancer: increasing clinical relevance. <i>Lancet Oncology</i> , The, 2018, 19, 3-5.	5.1	30
161	INPP4B promotes PI3KÎ±-dependent late endosome formation and Wnt/Î²-catenin signaling in breast cancer. <i>Nature Communications</i> , 2021, 12, 3140.	5.8	30
162	Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection. <i>OncoTargets and Therapy</i> , 2010, 4, 1.	1.0	29

#	ARTICLE	IF	CITATIONS
163	A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 95-117.	1.1	27
164	Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy. <i>Breast</i> , 2015, 24, 290-293.	0.9	27
165	Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 945-962.	1.4	26
166	PTPN2 elicits cell autonomous and non-cell autonomous effects on antitumor immunity in triple-negative breast cancer. <i>Science Advances</i> , 2022, 8, eabk3338.	4.7	22
167	Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells. <i>Cancer Research</i> , 2016, 76, 264-274.	0.4	21
168	Molecular analysis of hormone receptor positive (luminal) breast cancers – What have we learnt?. <i>European Journal of Cancer</i> , 2008, 44, 2813-2818.	1.3	20
169	Exercise Attenuates Cardiotoxicity of Anthracycline Chemotherapy Measured by Global Longitudinal Strain. <i>JACC: CardioOncology</i> , 2019, 1, 298-301.	1.7	20
170	Oncogene addiction and immunity. <i>Current Opinion in Oncology</i> , 2014, 26, 562-567.	1.1	19
171	Molecular Forecasting of Breast Cancer: Time to Move Forward With Clinical Testing. <i>Journal of Clinical Oncology</i> , 2006, 24, 721-722.	0.8	18
172	HER2-overexpressing breast cancer. <i>Current Opinion in Oncology</i> , 2011, 23, 547-558.	1.1	18
173	Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study. <i>PLoS Medicine</i> , 2020, 17, e1003363.	3.9	18
174	Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. <i>Lancet Oncology</i> , The, 2011, 12, 1162-1168.	5.1	17
175	Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 936-944.	0.8	17
176	Challenges in breast cancer clinical trial design in the postgenomic era. <i>Current Opinion in Oncology</i> , 2004, 16, 536-541.	1.1	16
177	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. <i>Npj Breast Cancer</i> , 2020, 6, 15.	2.3	16
178	Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer. <i>Cancer Research</i> , 2021, 81, GS3-01-GS3-01.	0.4	16
179	Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study. <i>Cancer Discovery</i> , 2022, 12, 2058-2073.	7.7	16
180	Molecular comparison of interval and screen-detected breast cancers. <i>Journal of Pathology</i> , 2019, 248, 243-252.	2.1	15

#	ARTICLE	IF	CITATIONS
181	Glomerulosclerosis: A paraneoplastic phenomenon?. <i>Nephrology</i> , 2004, 9, 387-391.	0.7	14
182	Breast cancer gene expression profiling: clinical trial and practice implications. <i>Pharmacogenomics</i> , 2005, 6, 49-58.	0.6	14
183	Abstract PD1-07: Exploratory analytical harmonization of PD-L1 immunohistochemistry assays in advanced triple-negative breast cancer: A retrospective substudy of IMpassion130. , 2020, , .		14
184	Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial. <i>Oncotarget</i> , 2015, 6, 30306-30316.	0.8	14
185	Advancing Immunotherapy in Metastatic Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 35.	1.3	13
186	Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, e181564.	3.4	13
187	Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer. <i>International Journal of Cancer</i> , 2020, 147, 266-276.	2.3	13
188	Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 467-470.	3.0	13
189	Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?. <i>Breast Care</i> , 2012, 7, 267-272.	0.8	12
190	The adverse mental health of carers: Does the patient diagnosis play a role?. <i>Maturitas</i> , 2015, 82, 134-138.	1.0	12
191	Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 25-31.	1.0	12
192	PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA502-LBA502.	0.8	12
193	Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. <i>European Journal of Cancer</i> , 2022, 166, 219-228.	1.3	12
194	Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data. <i>Genome Biology</i> , 2014, 15, 470.	3.8	11
195	Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: A retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy. <i>Breast</i> , 2014, 23, 473-481.	0.9	11
196	High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers. <i>JCO Precision Oncology</i> , 2017, 1, 1-13.	1.5	11
197	ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia. <i>Pathology</i> , 2019, 51, 345-348.	0.3	11
198	Metastatic Breast Cancer: TIL it is Too Late. <i>Clinical Cancer Research</i> , 2020, 26, 526-528.	3.2	11

#	ARTICLE	IF	CITATIONS
199	Assessment of Ovarian Function in Phase III (Neo)Adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation. <i>Journal of the National Cancer Institute</i> , 2021, , .	3.0	11
200	Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 599-606.	1.1	11
201	Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapy. <i>Oncotarget</i> , 2019, 10, 4612-4614.	0.8	11
202	Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis. <i>Breast</i> , 2021, 59, 183-192.	0.9	10
203	Gene Profiling Assay and Application: The Predictive Role in Primary Therapy. <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 124-127.	0.9	9
204	Exercise as a diagnostic and therapeutic tool for preventing cardiovascular morbidity in breast cancer patients—the BREast cancer EXercise InTervention (BREXIT) trial protocol. <i>BMC Cancer</i> , 2020, 20, 655.	1.1	9
205	Abstract PD14-07: Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086. , 2021, , .		9
206	Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer. <i>Endocrine-Related Cancer</i> , 2011, 18, 721-730.	1.6	8
207	Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 3-18.	0.7	8
208	The AURORA pilot study for molecular screening of patients with advanced breast cancer—a study of the breast international group. <i>Npj Breast Cancer</i> , 2017, 3, 23.	2.3	8
209	Novel Targeted Agents and Immunotherapy in Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 65-75.	1.8	8
210	Passion for immune checkpoint blockade in triple negative breast cancer: Comment on the IMpassion130 study. <i>Annals of Oncology</i> , 2019, 30, 13-16.	0.6	8
211	Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. <i>European Journal of Cancer</i> , 2022, 164, 39-51.	1.3	8
212	Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 47-59.	1.8	8
213	Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 update. <i>Breast</i> , 2022, 62, S29-S33.	0.9	7
214	A randomized cross-over trial to determine the effect of Cremophor EL on the pharmacodynamics and pharmacokinetics of carboplatin chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 407-414.	1.1	6
215	Investigating the positive relationship between tumor-infiltrating lymphocytes and trastuzumab therapy. <i>Immunotherapy</i> , 2014, 6, 803-805.	1.0	6
216	Looking Deep Into the Heterogeneity of Human Epidermal Growth Factor Receptor 2—Positive Breast Cancer: Can We Understand It Better?. <i>Journal of Clinical Oncology</i> , 2016, 34, 521-523.	0.8	6

#	ARTICLE	IF	CITATIONS
217	Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: Prediction of response to carboplatin-based chemotherapy.. Journal of Clinical Oncology, 2014, 32, 510-510.	0.8	6
218	Novel Targeted Agents and Immunotherapy in Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 65-75.	1.8	6
219	Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. Clinical Cancer Research, 2021, 27, 5607-5618.	3.2	5
220	Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials.. Journal of Clinical Oncology, 2015, 33, 511-511.	0.8	5
221	Tumor PIK3CA genotype and prognosis: A pooled analysis of 4,241 patients (pts) with early-stage breast cancer (BC).. Journal of Clinical Oncology, 2015, 33, 516-516.	0.8	5
222	Combining Radiotherapy and Immunotherapy in Metastatic Breast Cancer: Current Status and Future Directions. Biomedicines, 2022, 10, 821.	1.4	5
223	Feasibility of developing reliable gene expression modules from FFPE derived RNA profiled on Affymetrix arrays. PLoS ONE, 2018, 13, e0203346.	1.1	4
224	Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer. European Journal of Cancer, 2017, 72, 95-102.	1.3	3
225	Infiltrating immune cells in benign breast disease and risk of subsequent invasive breast cancer. Breast Cancer Research, 2021, 23, 15.	2.2	3
226	Plasma and tumor genomic correlates of response to BYL719 in PI3KCA mutated metastatic ER-positive breast cancer (ER+/HER2- BC).. Journal of Clinical Oncology, 2018, 36, 1055-1055.	0.8	3
227	Immunity and HER2-positive disease: never stop questioning. Annals of Oncology, 2015, 26, 2361-2362.	0.6	2
228	Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer: An Australian case series. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 377-382.	0.7	2
229	FINESSE: An open, three-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or nonamplified estrogen receptor-positive metastatic breast cancer.. Journal of Clinical Oncology, 2014, 32, TPS1134-TPS1134.	0.8	2
230	Investigating the role of tumor-infiltrating lymphocytes in advanced HER2-positive breast cancer. Chinese Clinical Oncology, 2018, 7, 2-2.	0.4	2
231	Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India. Asia-Pacific Journal of Clinical Oncology, 2021, ...	0.7	2
232	Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials. Breast, 2022, , .	0.9	2
233	Time to move forward from "first-generation" prognostic gene signatures in early breast cancer. Breast Cancer Research and Treatment, 2011, 128, 643-645.	1.1	1
234	Tumour-Infiltrating Lymphocytes (TILs) in Breast Cancer: a Predictive or a Prognostic Marker?. Current Breast Cancer Reports, 2015, 7, 59-70.	0.5	1

#	ARTICLE	IF	CITATIONS
235	Fine-tuning chemotherapy in the era of dual HER2 targeting. <i>Lancet Oncology</i> , The, 2018, 19, 1551-1554.	5.1	1
236	In the beginning, there was chaos: A perspective on the development of immuno-oncological biomarkers. <i>Seminars in Cancer Biology</i> , 2018, 52, v-vi.	4.3	1
237	Around the world and back again. <i>Nature Medicine</i> , 2019, 25, 1466-1466.	15.2	1
238	Deciphering clonality in aneuploid tumors using SNP array and sequencing data. <i>Genome Biology</i> , 2014, 15, 470.	13.9	1
239	Lack of correlation of neoantigens arising from tumor somatic mutations with tumor infiltrating lymphocytes (TILs) or survival in HER2-positive breast cancer (HER2+ BC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 613-613.	0.8	1
240	PIK3CA mutations in primary HER2-positive and triple negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 11061-11061.	0.8	1
241	Challenges of Creating New Tumor-Infiltrating Lymphocyte for Combating Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, , JCO2200284.	0.8	1
242	Vision and collaboration: essential ingredients for the future of breast cancer research. <i>Current Opinion in Oncology</i> , 2004, 16, 521-522.	1.1	0
243	Conference Scene: Advances in breast cancer translational research. <i>Breast Cancer Management</i> , 2012, 1, 197-199.	0.2	0
244	Modulation of Immune Response in Breast Cancer and Clinical Implications. <i>Annals of Oncology</i> , 2014, 25, iv6.	0.6	0
245	Immunology and Immunotherapy of Breast Cancer. , 2015, , 457-470.		0
246	Reply to A. Ocaña et al and P.G. Tsoutsou et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 1299-1300.	0.8	0
247	Molecular segmentation of luminal breast: Reality in 2015?. <i>Breast</i> , 2015, 24, S41-S43.	0.9	0
248	Abstract OT-36-01: Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2- LA/MBC). , 2021, ,		0
249	Extended adjuvant aromatase inhibitor therapy: less is more. <i>Med</i> , 2021, 2, 996-998.	2.2	0
250	Abstract 1220:PIK3CA mutations in primary HER2-positive and triple negative breast cancer.. , 2013, ,		0
251	Prognostic, predictive, and surrogate value of HER2 extracellular domain (ECD) for progression-free survival (PFS) in advanced breast cancer treated with lapatinib (lap): A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, 630-630.	0.8	0
252	Evaluation of PI3K-pathway activation status in matched primary (P) and metastatic (M) ER+/HER2- breast cancer (BC) lesions according to PIK3CA-mutation status.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11060-11060.	0.8	0

#	ARTICLE	IF	CITATIONS
253	Abstract P6-01-01: RANK/RANKL expression by immunohistochemistry (IHC) in young breast cancer (BC) patients and during pregnancy: Association with clinicopathologic features, gene expression profiles and patient outcome. , 2015, , .		0
254	Abstract ES6-3: Tumor infiltrating lymphocytes in breast cancer. , 2015, , .		0
255	Abstract CT135: Uncovering the genomic heterogeneity of multifocal breast cancer. , 2015, , .		0
256	Gene Expression Analysis: Applications. , 2016, , 137-149.		0
257	Abstract P5-19-03: What are the barriers to assessment of ovarian toxicity in breast cancer clinical trials?. Cancer Research, 2022, 82, P5-19-03-P5-19-03.	0.4	0
258	What's in a name? That which we call Immune Cells by any other name would all smell as sweet. Clinical Cancer Research, 2022, , .	3.2	0